The Winship Cancer Institute (WCI) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Its Director, Brian Leyland-Jones, MD, PhD, also serves as Associate Vice-President in the Woodruff Health Sciences Center and leads an expert team of Senior Leadership, Program Leaders, and Core Directors. The 152 WCI members engage in four scientific programs: Cancer Genetics and Epigenetics (CGE), Molecular Pathways and Biomarkers (MPB), Discovery and Drug Development (DDT), and Cancer Control and Population Sciences (CCPS). Shared core resources provide services in Clinical Trials, Cell Imaging and Microscopy, Biomarker Profiling, Biostatistics, and Human Tissue and Pathology. The WCI currently occupies dedicated facilities of over 350,000 nsf under the direct control of the Director. During the P20 Planning Grant period, the WCI's NCI funding grew from $9.49 million to its current mark of $25 million in NCI grants out of a total of $55.4 million in extramural, peer-reviewed cancer funding. This growth has been facilitated by the extensive recruiting of new faculty to Emory, resulting in 88 new recruits from 19 different departments across the Schools of Medicine, Public Health, Nursing, and Emory College. Other noteworthy accomplishments during this planning period have been substantial progress in clinical trials as measured by total accruals and accruals to investigator-initiated studies, and the success in team science awards, including multiple P01's, P20's, P60, the U54 Cancer Center for Nanotechnology Excellence, and a Head and Neck SPORE. The WCI has received extensive institutional support, including more than $95 million in University funding to support infrastructure and new initiatives, plus $103 million for the construction of the WCI building dedicated in 2002. Beyond funding, Emory has been committed to elevating the status of the cancer center within the University;enhancing the organizational position of the cancer center within the Woodruff Health Sciences Center;and ensuring the sustained authority of the Director. The WCI also benefits from intense support from its community partners, including the Georgia Cancer Coalition (GCC), which has provided over $28 million in support to 51 GCC Scholars among WCI members;the American Cancer Society;the CDC;and other area-based institutions, including the Georgia Institute of Technology and Morehouse School of Medicine. Developmental funds are requested for a Transgenic Mouse and Gene Targeting Core and essential Bioinformatics technology. The WCI is well-positioned to continue to advance its progress as it pursues NCI-designation as a cancer center, and to fulfill its mission to reduce the burden of cancer throughout the state of Georgia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA138292-03S2
Application #
8322912
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2009-04-07
Project End
2012-07-31
Budget Start
2011-04-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2011
Total Cost
$75,000
Indirect Cost
Name
Emory University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Cassidy, Richard J; Switchenko, Jeffrey M; Yushak, Melinda L et al. (2018) The importance of surgery in scalp angiosarcomas. Surg Oncol 27:A3-A8
Owonikoko, Taofeek K; Busari, Adeniyi K; Kim, Sungjin et al. (2018) Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. Oncology 95:138-146
Koff, Jean L; Li, Jing-Xia; Zhang, Xinyan et al. (2018) Impact of the posttransplant lymphoproliferative disorder subtype on survival. Cancer 124:2327-2336
Dennison, Cori; King, Adrian R; Rutledge, Hannah et al. (2018) HPV Vaccine-Related Research, Promotion and Coordination in the State of Georgia: A Systematic Review. J Community Health :
Dhere, Vishal; Edelman, Scott; Waller, Edmund K et al. (2018) Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia. Leuk Lymphoma 59:837-843
Steuer, Conor E; Griffith, Christopher C; Nannapaneni, Sreenivas et al. (2018) A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Mol Cancer Ther 17:710-716
Pillai, Rathi N; Behera, Madhusmita; Owonikoko, Taofeek K et al. (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer 124:271-277
King, Adrian R; Moon, Tamira; Agnew, Gena et al. (2018) Human Papillomavirus Vaccination in Georgia: Evaluating the Georgia HPV Work Group. J Community Health :
Ivanov, Andrei A; Revennaugh, Brian; Rusnak, Lauren et al. (2018) The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery. Bioinformatics 34:1183-1191
Mehta, Neeti D; Haroon, Ebrahim; Xu, Xiaodan et al. (2018) Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain Behav Immun 73:725-730

Showing the most recent 10 out of 331 publications